VIVUS, Inc. (VVUS) Earnings: An Early Look

Page 1 of 2

Earnings season is now starting to wind down, with most companies already having reported their quarterly results. But there are still some companies left to report, and VIVUS, Inc. (NASDAQ:VVUS) is about to release its quarterly earnings report. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.

VIVUS, Inc. (NASDAQ:VVUS)VIVUS was fortunate enough to be the first company to bring a new anti-obesity drug to market, but Qsymia hasn’t been everything that investors had hoped it would be. Let’s take an early look at what’s been happening with VIVUS over the past quarter and what we’re likely to see in its quarterly report on Monday.

Stats on VIVUS

Analyst EPS Estimate ($0.44)
Year-Ago EPS ($0.14)
Revenue Estimate $3.34 million
Change From Year-Ago Revenue NM
Earnings Beats in Past 4 Quarters
0

Sources: Yahoo! Finance, S&P Capital IQ. NM = not meaningful; VIVUS had no revenue in the year-ago period.

Will VIVUS finally pay off for investors?
Analysts aren’t too optimistic about VIVUS coming into its report, as they’ve cut nearly a dime off earnings-per-share estimates for the quarter over the past few months, and for full-year 2013, current consensus has fallen by more than $0.25 per share over the same time frame. But investors haven’t been deterred by those concerns, as the stock is up more than 25% since mid-November.

VIVUS wasn’t the first company to get its obesity drug approved, as Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) managed to get its Belviq drug past the FDA gates first. But Arena hasn’t been able to release Belviq pending DEA classification, VIVUS got a head start on sales. After a slow start, sales have picked up somewhat, with the company saying that sales in the late November to late December period rose 68% from the prior four-week period.

More recently, though, questions have arisen about whether any blockbuster anti-obesity drug will emerge from the fray. Safety issues have again come up, with the regulatory agency responsible for approving drugs in the European Union rejecting VIVUS’s appeal pending more clinical data on potential risks of cardiovascular problems. Moreover, even if safety concerns with anti-obesity drugs get resolved successfully, most medications can’t solve obesity without accompanying changes in patient behavior.

Moreover, cost has been a concern, as 30% of patients have given up their prescriptions. Aetna Inc. (NYSE:AET) changed its policies to call Qsymia and Belviq “medically necessary” and therefore allowed them to qualify for drug benefits in many cases, and pharmacy benefits manager Express Scripts Holding Company (NASDAQ:ESRX) has added Qsymia to its national formulary, opening the door to copayments of $50 to $60 for many patients. Other insurance providers may conclude that encouraging obesity treatment leads to lower overall health costs in the long run and therefore make the same change.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Reign of Terror: The 10 Most Ruthless Politicians in History

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!